Choate, Hall & Stewart LLP Podcast

Choate LLP
  • 0.0 (0)
  • BUSINESS

Our unique business model allows us to stand out in a legal marketplace which is crowded with firms who look, act and think alike.

  1. Research Security Enforcement Updates

    06/28/2024

    Research Security Enforcement Updates

    In this episode of the Enforcement and Investigations Podcast Series, Christine Savage and Mark McPherson discuss recent research security enforcement actions involving the University of Florida and Cleveland Clinic, as well as the biotechnology company Sigma-Aldrich. The discussion offers insights and takeaways from these matters that research security and compliance professionals can use to enhance their institutions’ research security programs, and highlights the impact of cooperating with the DOJ’s National Security Division Voluntary Self-Disclosure Program.

    19 min
  2. Demystifying Private Investments

    06/27/2024

    Demystifying Private Investments

    In this episode of the Choate Family Office Services Podcast Series, Lanny Thorndike, President of Choate Investment Advisors, and Alison Svizzero, a Portfolio Manager and Head of Private Equity, explore the potential benefits of private equity investments for families looking to diversify their portfolios. The discussion covers how the addition of private equity investments to a portfolio can boost performance, broaden the opportunity offerings, and provide diversification benefits.

    13 min
  3. Salix v. Norwich Patent Infringement Opinion and the Implications of a Post-Trial ANDA Amendment and Section 8 Carveout

    05/01/2024

    Salix v. Norwich Patent Infringement Opinion and the Implications of a Post-Trial ANDA Amendment and Section 8 Carveout

    In this episode of our Life Sciences Insights podcast series, Sophie Wang and Madison Garrett discuss the Federal Circuit’s recent opinion in a patent infringement case between Salix Pharmaceuticals and Norwich Pharmaceuticals. The opinion arises out of Hatch-Waxman litigation concerning Norwich’s Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Salix’s drug, rifaximin, marketed under the brand name Xifaxan®. Sophie and Madison discuss two main components of the opinion: (1) the use of a clinical trial protocol as prior art to render obvious a claim directed to a method of treatment with particular dosages, and whether that supports a reasonable expectation of success, and (2) the implications of a post-trial ANDA amendment with a section 8 carveout (a.k.a. skinny label) on an injunction order from the litigated case.

    13 min
  4. Moab v. Macquarie Decision Narrows the Scope of 10b-5 Liability for Securities Litigation Cases

    04/30/2024

    Moab v. Macquarie Decision Narrows the Scope of 10b-5 Liability for Securities Litigation Cases

    In this episode of our Litigation podcast series, Mike Gass, Chair of Choate’s securities litigation practice, and Kristen Perriello, a Principal in the Government Enforcement Group discuss the Supreme Court’s significant securities law decision in Macquarie Infrastructure Corp. v. Moab Partners. The decision focuses on whether Rule 10b-5(b) prohibits pure omissions or only half-truths. Mike and Kristen will provide an overview of the case and focus on the legal and practical takeaways arising from the decision.

    8 min

  5. 10/23/2023

    Utilizing ESG as Criteria in Investment Analysis

    In this episode of the Family Office Services Podcast Series, Choate Investment Advisors’ Erin Kerr and Alison Svizzero discuss how environmental, social, and governance (ESG) criteria are used by investors in evaluating companies, in addition to traditional fundamental analysis, to determine long-term performance. ESG has increased as an area of interest for investors over the past decade. Erin, who is a ChoateIA Chief Compliance Officer and the Chief Investment Officer, and Alison, a Portfolio Manager and the Head of Private Equity Investing, provide a comprehensive overview and debunk myths related to utilizing ESG as investment criteria.

    15 min
  6. Trending False Claims Act Cases

    07/12/2023

    Trending False Claims Act Cases

    In this episode of Choate’s Enforcement & Investigations Updates Podcast Series, Emily Hodge and Kristen Perriello discuss recent significant cases and decisions surrounding the False Claims Act - including legal and practical takeaways arising from the Supreme Court’s decisions in the SuperValu case and the Polansky qui tam case, as well as the string of differing decisions in the circuit courts relating to the causation element in False Claims Act cases premised on Anti-Kickback Statute violations.

    11 min
  7. A Debrief of the Supreme Court’s Decision in Amgen v. Sanofi

    06/12/2023

    A Debrief of the Supreme Court’s Decision in Amgen v. Sanofi

    In this episode of Choate’s Life Sciences Insights Podcast Series, Sophie Wang, Stephanie Schonewald and Peter Flynn discuss the US Supreme Court’s opinion in Amgen v. Sanofi, one of this term’s most highly-watched cases for our clients concerning the law of enablement as it applies to patents directed to antibody therapeutics. Choate submitted an amicus brief in this case on behalf of Nobel Laureate and distinguished immunologist, Sir Gregory Winter, and a collection of other notable scientists, in support of Sanofi and Regeneron.

    21 min
  8. Investment Implications of the Current Debt Ceiling Negotiations

    05/23/2023

    Investment Implications of the Current Debt Ceiling Negotiations

    In this episode of the Family Office Services podcast, Tamer Alamuddin and Christine Wright of Choate Investment Advisors discuss the current U.S. debt ceiling, related political gridlock and fears about financial instability. In addition to giving an overall understanding of the debt ceiling and its historical framework, Tamer and Christine will share the potential investment implications related to the current situation in the U.S.

    12 min
See All (28)

About

Our unique business model allows us to stand out in a legal marketplace which is crowded with firms who look, act and think alike.

Information